Korean J Urol.  2014 Dec;55(12):797-801. 10.4111/kju.2014.55.12.797.

Histologic Variability and Diverse Oncologic Outcomes of Prostate Sarcomas

• Sohn M
• Kwon T
• Jeong IG
• Hong S
• You D
• Hong JH
• Ahn H
• Kim CS

• KMID: 2070093
• DOI: http://doi.org/10.4111/kju.2014.55.12.797

Abstract

PURPOSE
Primary prostate sarcomas are a rare type of prostate cancer that account for less than 0.1% of primary prostate malignancies. We analyzed the experience of a single institution with prostate sarcoma over 20 years.
MATERIALS AND METHODS
In this case series, the medical records of 20 patients with prostate sarcoma were reviewed from June 1990 to December 2013 to identify symptoms at presentation, diagnostic procedures, metastasis presence and development, histologic subtype, French Federation Nationale des Centres de Lutte Contre le Cancer grade, primary tumor grade and size, and treatment sequence, including surgery and preoperative and postoperative therapies. The average follow-up period was 23.6 months (range, 1.4-83.3 months).
RESULTS
The average patient age was 46.3+/-16.7 years. Most patients presented with lower urinary tract symptoms (55%). The histologic subtype was spindle cell sarcoma in five patients (25%), rhabdomyosarcoma in three patients (15%), synovial sarcoma in three patients (15%), liposarcoma in three patients (15%), stromal sarcoma in three patients (15%), and Ewing sarcoma, nerve sheath tumor, and adenocarcinoma with sarcomatoid component (5% each). For liposarcoma, two patients were alive after complete surgical resection and had a good prognosis. At last follow-up, 15 patients had died of sarcoma. The 2- and 5-year actuarial survival rates for all 20 patients were 53% and 12%, respectively (medial survival, 20 months).
CONCLUSIONS
The disease-specific survival rate of prostate sarcoma is poor. However, sarcoma that is detected early shows a better result with proper management including surgical intervention with radio-chemotherapy than with no treatment. Early diagnosis and complete surgical resection offer patients the best curative chance.

Keyword

Liposarcoma; Prostate; Rhabdomyosarcoma; Sarcoma

MeSH Terms

Adult
Aged
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Prognosis
Prostatectomy/methods
Prostatic Neoplasms/diagnosis/*pathology/therapy
Retrospective Studies
Sarcoma/diagnosis/*pathology/secondary/therapy
Treatment Outcome
Young Adult

Reference

1. Mondaini N, Palli D, Saieva C, Nesi G, Franchi A, Ponchietti R, et al. Clinical characteristics and overall survival in genitourinary sarcomas treated with curative intent: a multicenter study. Eur Urol. 2005; 47:468–473.

2. Dotan ZA, Tal R, Golijanin D, Snyder ME, Antonescu C, Brennan MF, et al. Adult genitourinary sarcoma: the 25-year Memorial Sloan-Kettering experience. J Urol. 2006; 176:2033–2038.

3. Smith BH, Dehner LP. Sarcoma of the prostate gland. Am J Clin Pathol. 1972; 58:43–50.

4. Sexton WJ, Lance RE, Reyes AO, Pisters PW, Tu SM, Pisters LL. Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. J Urol. 2001; 166:521–525.

5. Ren FY, Lu JP, Wang J, Ye JJ, Shao CW, Wang MJ. Adult prostate sarcoma: radiological-clinical correlation. Clin Radiol. 2009; 64:171–177.

6. Probert JL, O'Rourke JS, Farrow R, Cox P. Stromal sarcoma of the prostate. Eur J Surg Oncol. 2000; 26:100–101.

7. Wu HY, Snyder HM 3rd, Womer RB. Genitourinary rhabdomyosarcoma: which treatment, how much, and when? J Pediatr Urol. 2009; 5:501–506.

8. Aguilar B, Villalobos M, Sotomayor M. Phyllodes tumor of the prostate. Urology. 2009; 73:272.

9. Bannowsky A, Probst A, Dunker H, Loch T. Rare and challenging tumor entity: phyllodes tumor of the prostate. J Oncol. 2009; 2009:241270.

10. Subramanian VS, Coburn M, Miles BJ. Carcinosarcoma of the prostate with multiple metastases: case report and review of the literature. Urol Oncol. 2005; 23:181–183.

11. Wang X, Liu L, Tang H, Rao Z, Zhan W, Li X, et al. Twenty-five cases of adult prostate sarcoma treated at a high-volume institution from 1989 to 2009. Urology. 2013; 82:160–165.

12. Janet NL, May AW, Akins RS. Sarcoma of the prostate: a single institutional review. Am J Clin Oncol. 2009; 32:27–29.

13. Russo P. Urologic sarcoma in adults. Memorial Sloan-Kettering Cancer Center experience based on a prospective database between 1982 and 1989. Urol Clin North Am. 1991; 18:581–588.

14. Ferrer FA, Isakoff M, Koyle MA. Bladder/prostate rhabdomyosarcoma: past, present and future. J Urol. 2006; 176(4 Pt 1):1283–1291.

15. Iacovelli R, Altavilla A, Ciardi A, Urbano F, Manai C, Gentile V, et al. Clinical and pathological features of primary renal synovial sarcoma: analysis of 64 cases from 11 years of medical literature. BJU Int. 2012; 110:1449–1454.

16. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, Goodwin L, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012; 344:d7894.

17. Ducimetiere F, Lurkin A, Ranchere-Vince D, Decouvelaere AV, Peoc'h M, Istier L, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011; 6:e20294.

18. Zhang G, Chen KK, Manivel C, Fraley EE. Sarcomas of the retroperitoneum and genitourinary tract. J Urol. 1989; 141:1107–1110.

19. Narayana AS, Loening S, Loening V, Culp DA. Sarcoma of the urinary bladder and prostate in children. Eur Urol. 1978; 4:401–404.

20. Ahlering TE, Weintraub P, Skinner DG. Management of adult sarcomas of the bladder and prostate. J Urol. 1988; 140:1397–1399.

21. Cho SY, Moon KC, Cheong MS, Kwak C, Kim HH, Ku JH. Localized resectable genitourinary sarcoma in adult Korean patients: experiences at a single center. Yonsei Med J. 2011; 52:761–767.

22. Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2011; 22:1266–1272.

23. Aragon-Ching JB, Maki RG. Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery. Cancer Invest. 2012; 30:300–308.

24. Lee G, Lee SY, Seo S, Jeon S, Lee H, Choi H, et al. Prognostic factors and clinical outcomes of urological soft tissue sarcomas. Korean J Urol. 2011; 52:669–673.

25. Na JC, Choi KH, Yang SC, Han WK. Surgical experience with retroperitoneal liposarcoma in a single korean tertiary medical center. Korean J Urol. 2012; 53:310–316.